{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:15:05Z","timestamp":1778901305922,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022896","name":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","doi-asserted-by":"publisher","award":["2201"],"award-info":[{"award-number":["2201"]}],"id":[{"id":"10.13039\/501100022896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:29:09Z","timestamp":1771676949000},"page":"472-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide"],"prefix":"10.1016","volume":"9","author":[{"given":"Barak","family":"Talmor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Gianacas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thean Hsiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsha","family":"Anton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharad","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganes","family":"Pranavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haryana M.","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel R.","family":"Denmeade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha R.","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"Fontela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Crumbaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.02.004_b0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.02.004_b0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0970-1591.52907","article-title":"Adverse effects of androgen deprivation therapy in prostate cancer: current management issues","volume":"25","author":"Bagrodia","year":"2009","journal-title":"Indian J Urol"},{"key":"10.1016\/j.euo.2026.02.004_b0015","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71149","article-title":"Comparison of disease progression from prostate cancer diagnosis to metastatic or nonmetastatic castrate\u2010resistant prostate cancer (CRPC) patients: CaPA study","volume":"14","author":"Costa","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2026.02.004_b0020","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.02.004_b0025","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.02.004_b0030","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.02.004_b0035","first-page":"339","article-title":"Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.euo.2026.02.004_b0040","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/pros.21196","article-title":"Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen\/ablation in men with castration resistant prostate cancer","volume":"70","author":"Denmeade","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2026.02.004_b0045","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.trecan.2025.04.009","article-title":"Prospects for understanding and exploiting the consequences of hyperactivation lethality","volume":"11","author":"Shaw","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.euo.2026.02.004_b0050","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/0008-5472.CAN-04-3992","article-title":"Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice","volume":"65","author":"Chuu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2026.02.004_b0055","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.93.21.11802","article-title":"Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride","volume":"93","author":"Umekita","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euo.2026.02.004_b0060","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.613","article-title":"Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements","volume":"42","author":"Haffner","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2026.02.004_b0065","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162396","article-title":"Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC","volume":"132","author":"Sena","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euo.2026.02.004_b0070","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3390\/biomedicines11072084","article-title":"Bipolar androgen therapy: when excess fuel extinguishes the fire","volume":"11","author":"Nabavi","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.euo.2026.02.004_b0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(17)30906-3","article-title":"Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study","volume":"19","author":"Teply","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.02.004_b0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.euo.2026.02.004_b0085","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.20.02759","article-title":"TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer","volume":"39","author":"Denmeade","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.02.004_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1125838","article-title":"Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: a systematic review","volume":"13","author":"You","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.euo.2026.02.004_b0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.18773\/austprescr.2020.061","article-title":"Darolutamide for prostate cancer","volume":"43","author":"Prescriber","year":"2020","journal-title":"Aust Prescr"},{"key":"10.1016\/j.euo.2026.02.004_b0100","unstructured":"DrugBank. Testosterone enanthate. https:\/\/go.drugbank.com\/drugs\/DB13944."},{"key":"10.1016\/j.euo.2026.02.004_b0105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/pst.1983","article-title":"Two-stage phase II survival trial design","volume":"19","author":"Wu","year":"2020","journal-title":"Pharm Stat"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2026.02.004_b0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.2025.43.5_suppl.178","article-title":"Extreme bipolar androgen therapy: alternating darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer (mCRPC; ExBAT trial\/LACOG 0620)","volume":"43","author":"Isaacsson","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.02.004_b0115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","article-title":"Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy","volume":"194","author":"Grossmann","year":"2011","journal-title":"Med J Aust"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:35:15Z","timestamp":1778898915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931126000416"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.004","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}